Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGPU NASDAQ:CNXU NASDAQ:SGHT NASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$7.08$6.62$1.03▼$32.10$76.60M3.43223,504 shs75,991 shsCNXUConexeu Sciences$10.86$0.00$9.60▼$18.79$290.59MN/A78,064 shs70,206 shsSGHTSight Sciences$5.45$4.93$3.11▼$9.24$296.53M2.38189,346 shs216,364 shsTMCITreace Medical Concepts$4.21$3.20$1.17▼$7.78$273.12M1.371.16 million shs460,662 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%-1.12%-13.34%+73.96%+707,999,900.00%CNXUConexeu Sciences0.00%-0.91%-32.13%+1,085,999,900.00%+1,085,999,900.00%SGHTSight Sciences0.00%-4.22%+18.48%+54.83%+31.01%TMCITreace Medical Concepts0.00%-5.61%+14.09%+190.34%-30.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGPUPredictive Oncology$7.08$6.62$1.03▼$32.10$76.60M3.43223,504 shs75,991 shsCNXUConexeu Sciences$10.86$0.00$9.60▼$18.79$290.59MN/A78,064 shs70,206 shsSGHTSight Sciences$5.45$4.93$3.11▼$9.24$296.53M2.38189,346 shs216,364 shsTMCITreace Medical Concepts$4.21$3.20$1.17▼$7.78$273.12M1.371.16 million shs460,662 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGPUPredictive Oncology0.00%-1.12%-13.34%+73.96%+707,999,900.00%CNXUConexeu Sciences0.00%-0.91%-32.13%+1,085,999,900.00%+1,085,999,900.00%SGHTSight Sciences0.00%-4.22%+18.48%+54.83%+31.01%TMCITreace Medical Concepts0.00%-5.61%+14.09%+190.34%-30.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGPUPredictive Oncology 1.00SellN/AN/ACNXUConexeu Sciences 2.50Moderate Buy$20.0084.16% UpsideSGHTSight Sciences 2.44Hold$8.1449.43% UpsideTMCITreace Medical Concepts 1.86Reduce$4.7713.30% UpsideCurrent Analyst Ratings BreakdownLatest AGPU, SGHT, CNXU, and TMCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026CNXUConexeu Sciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold6/22/2026CNXUConexeu Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.006/15/2026TMCITreace Medical Concepts Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026AGPUPredictive Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026SGHTSight Sciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$4.35 ➝ $5.155/11/2026SGHTSight Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026AGPUPredictive Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026TMCITreace Medical Concepts Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/10/2026SGHTSight Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGPUPredictive Oncology$50.29K1,523.29N/AN/A$11.69 per share0.61CNXUConexeu SciencesN/AN/AN/AN/AN/AN/ASGHTSight Sciences$77.36M3.83N/AN/A$1.21 per share4.50TMCITreace Medical Concepts$212.69M1.28N/AN/A$1.37 per share3.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGPUPredictive Oncology-$233.10M-$8.18N/AN/AN/A-470,383.31%-7,363.67%-626.32%N/ACNXUConexeu SciencesN/AN/AN/AN/AN/AN/AN/AN/AN/ASGHTSight Sciences-$38.43M-$0.71N/AN/AN/A-46.83%-52.34%-28.49%8/6/2026 (Estimated)TMCITreace Medical Concepts-$59M-$0.97N/AN/AN/A-29.44%-67.04%-30.28%8/6/2026 (Estimated)Latest AGPU, SGHT, CNXU, and TMCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/15/2026Q2 2026CNXUConexeu SciencesN/A-$0.11N/A-$0.11N/AN/A5/15/2026Q1 2026AGPUPredictive OncologyN/A-$0.36N/A-$0.36N/A$0.04 million5/8/2026Q1 2026TMCITreace Medical Concepts-$0.31-$0.28+$0.03-$0.28$45.96 million$47.20 million5/6/2026Q1 2026SGHTSight Sciences-$0.19-$0.24-$0.05-$0.24$18.47 million$19.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGPUPredictive OncologyN/AN/AN/AN/AN/ACNXUConexeu SciencesN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGPUPredictive OncologyN/A8.898.89CNXUConexeu SciencesN/AN/AN/ASGHTSight Sciences0.685.865.48TMCITreace Medical Concepts0.723.582.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGPUPredictive Oncology9.04%CNXUConexeu SciencesN/ASGHTSight Sciences55.51%TMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipAGPUPredictive Oncology1.21%CNXUConexeu SciencesN/ASGHTSight Sciences30.90%TMCITreace Medical Concepts23.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGPUPredictive Oncology3010.82 million10.69 millionN/ACNXUConexeu Sciences426.76 millionN/AN/ASGHTSight Sciences21054.41 million37.60 millionOptionableTMCITreace Medical Concepts25064.87 million49.68 millionOptionableAGPU, SGHT, CNXU, and TMCI HeadlinesRecent News About These CompaniesTMCI Share News TodayJune 30, 2026 | uk.investing.comTreace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant SystemJune 18, 2026 | globenewswire.comTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 22,887 SharesJune 12, 2026 | insidertrades.comTreace to Present at the Sidoti Small Cap ConferenceJune 11, 2026 | globenewswire.comTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Acquires 50,000 SharesJune 2, 2026 | insidertrades.comTreace Medical Concepts Balances Growth With Earnings StrainJune 1, 2026 | tipranks.comJohn Treace Purchases 4,508 Shares of Treace Medical Concepts (NASDAQ:TMCI) StockMay 29, 2026 | insidertrades.comTreace Medical Shareholders Back Directors, Pay and AuditorMay 20, 2026 | tipranks.comTreace Medical Concepts, Inc.May 15, 2026 | edition.cnn.comTreace Medical Concepts (NASDAQ:TMCI) CEO John Treace Buys 43,000 SharesMay 15, 2026 | insidertrades.comTreace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 12, 2026 | globenewswire.comTreace Medical Concepts Inc (TMCI) Q1 2026 Earnings Call Highlights: Navigating Revenue ...May 9, 2026 | finance.yahoo.comTreace Medical Concepts: Q1 Earnings SnapshotMay 8, 2026 | myjournalcourier.comMTreace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue EstimatesMay 8, 2026 | zacks.comTreace Medical Concepts Reports First Quarter 2026 Financial ResultsMay 8, 2026 | globenewswire.comTreace Medical Concepts Inc (TMCI) Q1 2026 Earnings Report Preview: What To ExpectMay 7, 2026 | finance.yahoo.comHow The Treace Medical Concepts (TMCI) Story Is Shifting With Mixed Analyst ExpectationsMay 3, 2026 | finance.yahoo.comTreace Medical Concepts, Inc. to Release First Quarter 2026 Financial Results and Host Conference CallApril 24, 2026 | quiverquant.comQTreace to Report First Quarter 2026 Financial Results on May 8, 2026April 24, 2026 | globenewswire.comHow The Treace Medical Concepts (TMCI) Narrative Is Shifting With New Targets And Product PlansApril 18, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGPU, SGHT, CNXU, and TMCI Company DescriptionsPredictive Oncology NASDAQ:AGPU$7.08 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$7.15 +0.07 (+0.99%) As of 07/2/2026 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.Conexeu Sciences NASDAQ:CNXU$10.86 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$10.86 0.00 (-0.05%) As of 07/2/2026 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.Sight Sciences NASDAQ:SGHT$5.45 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$5.46 +0.00 (+0.09%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.Treace Medical Concepts NASDAQ:TMCI$4.21 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$4.20 -0.01 (-0.24%) As of 07/2/2026 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
